Connect with us

BioPharma

iQSTEL Inc (OTCQX: IQST) Heating Up as Co Rejects Formal Offer for EV Business (More on 5G LOI, Up Listing, Telecom Business Growth)

Published

on

iiQSTEL Inc (OTCQX: IQST) is making a big move up in recent days since reversing off $0.36 lows. This week  the Company reported it has received a formal offer to purchase iQSTEL’s entire electric vehicle (EV) subsidiary.  The offer values iQSTEL’s EVOSS Electric Vehicle operation substantially higher than iQSTEL’s internal valuation.  The buyer is a US company that has filed an S-1 for an initial public offering (IPO) on Nasdaq. According to IQST management “The offer to acquire iQSTEL’s electric vehicle business independent of iQSTEL’s telecommunications business also demonstrates that it may be in the best interest of iQSTEL shareholders for the company to pursue separate Nasdaq listings for its telecommunications and electric vehicle businesses.  However, iQSTEL Management and the Board of Directors believe it would be best to pursue such independent Nasdaq listings directly and separate from any merger and acquisition in order to minimize any potential dilution to the iQSTEL shareholders and optimize the market valuation of each separate business.  Accordingly, iQSTEL Management and the Board of Directors has decided to decline the subject offer” 

IQST was one of the biggest runners of early 2021 skyrocketing from pennies to $2 per share before coming down and forming a new base at $0.50.  Microcapdaily reported on the rise of IQST from the very beginning featuring the stock in 2020 when it was 0.07 per share. We reported on IQST as the Company launched its EVOSS electric motorcycles and announced plans to up list to the NASDAQ. According to IQST CEO Leandro Iglesias: “the Company is well positioned to endure the prevailing market conditions and continue in the execution of our plan to achieve $90 million in revenue this year with positive net income.  We have adequate cash to avoid any fundraising until next year. We are continuing to prepare for a Nasdaq up-listing and will look for an opportunity to do so when market conditions can support an organic increase in iQSTEL’s share price to the Nasdaq minimum listing standard. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

iQSTEL Inc (OTCQX: IQST) is a US-based publicly-listed company offering leading-edge Telecommunication, Technology and Fintech Services for Global Markets, with presence in 13 countries.  The company provides services to the Telecommunications, Electric Vehicle (EV), Liquid Fuel Distribution, Chemical and Financial Services Industries. iQSTEL has 4 Business Divisions: Telecom, Technology, Fintech and Blockchain, with worldwide B2B and B2C customer relations operating through its subsidiaries: Etelix, SwissLink, QGlobal SMS, SMSDirectos, IoT Labs, Global Money One and itsBchain. The Company has an extensive portfolio of products and services for its clients: SMS, VoIP, 4G & 5G international infrastructure connectivity, Cloud-PBX, OmniChannel Marketing, IoT Smart Electric Vehicle Platform, iQ Batteries for Electric Vehicles, IoT Smart Gas Platform, IoT Smart Tank Platform, Visa Debit Card, Money Remittance, Mobile Number Portability Application MNPA (Blockchain Platform) and Settlement & Payments Marketplace (Blockchain Platform). 

IQST Telecom business is the aircraft carrier in the iQSTEL fleet of mobile and connected solutions. The iQSTEL Telecom Division is on track to achieve the best year since its founding and all 6 of the Company’s Telecom subsidiaries (Etelix, SwissLink, QGlobal SMS, IoTLabs, Smartbiz and Whisl) are growing revenue, increasing gross profit, and contributing to an increasing net income, all while gaining higher and higher customer recognition. 

Earlier this month IQST entered into an LOI whereby, for the purposes of an intended acquisition, the company will conduct due diligence on 2,300 miles of fiber-optic network located in America. iQSTEL has been in discussions with the target acquisition over the past two years first announcing a potential partnership in May of 2021. The acquisition would accelerate iQSTEL’s entry into the 5G marketplace, expected to reach $700 billion by 2025. Following a 90-day due-diligence period, iQSTEL is expected to make an offer for the acquisition of 100% of the capital stock of the company that owns the fiber-optic network. 

To Find out the inside Scoop on IQST Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

IQST

IQST continues to experienced record revenue growth and reported a 37% increase in revenue to $19.42 million in Q1 compared to the same period in 2021 in its Q1 filing. The company is approaching breakeven posting a substantial bottom line improvement reducing its net loss by 72% compared to the same period last year.  Stockholder’s equity increased 410% to almost $7 million compared to Q1 2021 surpassing the Nasdaq minimum listing requirement. The current financial results do not include the recently announced acquisitions of Smartbiz and Whisl that are expected to add $11.6 Million revenue and $1.34 Million positive net income to the company’s existing revenue and income on yearly basis. The company will start to show this impact in Q2 partially and in Q3 in full. IQST also reported $7.4 million in revenue for the month of April 2022 based on preliminary accounting. The revenue in April 2022 increased 40% over the revenue reported in April 2021 and increased 14% over the average monthly revenue reported in Q1 2022. Management indicates that the year-to-date results surpass expectations in regard to the company’s $90 million revenue, net income positive FY-2022 forecast. 

We have reported many times on IQST entry into the booming EV marketplace with its first batch of EV Motorcycles having rolled off the production line. The first production run was shipped to Spain for distribution in Europe, the United States, and Panama, for distribution in Latin America. The company is producing four different model EV Motorcycles resulting in the combination of two different electric motors, a 2 kw and a 3 kW, and two different batteries, a 50 amp-h and a 75 amp-h.  The four different model EVOSS EV Motorcycles are designated as the EVOSS 250, the EVOSS 275, the EVOSS 350 and the EVOSS 375.  All EVOSS EV Motorcycles include a removable 72 Volt battery with a charging unit. The 4 models are intended to allow consumers to select the right solution for their specific geography and purpose – city or open road; hills or flats, personal transportation, or delivery service. The current EVOSS EV Motorcycles have a 100 km range per battery charge. The Company’s manufacturing partner in China is thoroughly testing the EVOSS EV Motorcycles to ensure specification compliance.  The tests include driving the EV Motorcycles over a 22-degree slope. 

The Company continues to make progress; the new EV Motorcycles (EVOSS), MasterCard Fintech Ecosystem (MAXMO), and Internet of Things (IoTSmart Gas/Tank) solutions are all fully developed, market tested and ready to begin generating high margin revenues. 

The first batch of EVOSS EV Motorcycles have received excellent customer reviews.  We are now working on the commercial launch in 4 countries this year. 

The Company announced its first MasterCard Fintech Ecosystem business partnership and is now working on three additional partnerships that we expect to fast track the rapid growth of our MasterCard Fintech Ecosystem. 

The IoTSmartGas/Tank has been deployed with a Fortune 500 chemical corporation customer. We expect to soon announce the results of this first deployment and then begin a global sales and marketing campaign. 

 For More on IQST Subscribe Right Now!

Currently trading at a $68,934,385 market valuation IQST has 149,857,358 shares outstanding and trades on the OTCQX. The Company has $9.8 million in assets, including $4.2 million in cash vs. $2.9 million in liabilities and big revenues reporting $19,419,310 for the 3 months ended March 31, 2022 compared to $14,197,611 for the same period last year. The stock is moving steadily northbound since reversing off $0.36 lows. This week the Company reported it has received a formal offer to purchase iQSTEL’s entire electric vehicle (EV) subsidiary.  The offer values iQSTEL’s EVOSS Electric Vehicle operation substantially higher than iQSTEL’s internal valuation.  The buyer is a US company that has filed an S-1 for an initial public offering (IPO) on Nasdaq. According to IQST management “The offer to acquire iQSTEL’s electric vehicle business independent of iQSTEL’s telecommunications business also demonstrates that it may be in the best interest of iQSTEL shareholders for the company to pursue separate Nasdaq listings for its telecommunications and electric vehicle businesses.  However, iQSTEL Management and the Board of Directors believe it would be best to pursue such independent Nasdaq listings directly and separate from any merger and acquisition in order to minimize any potential dilution to the iQSTEL shareholders and optimize the market valuation of each separate business.  Accordingly, iQSTEL Management and the Board of Directors has decided to decline the subject offer” Things seem to be on track at IQST. According to IQST CEO Leandro Iglesias: “the Company is well positioned to endure the prevailing market conditions and continue in the execution of our plan to achieve $90 million in revenue this year with positive net income.  We have adequate cash to avoid any fundraising until next year. We are continuing to prepare for a Nasdaq up-listing and will look for an opportunity to do so when market conditions can support an organic increase in iQSTEL’s share price to the Nasdaq minimum listing standard. We will be updating on IQST when more details emerge so make sure you are subscribed to Microcapdaily.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

sclosure: we hold no position in IQST either long or short and we have not been compensated for this article.

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.